Mark Stevenson
Ingersoll RandAbout Mark P. Stevenson
Mark P. Stevenson (age 62) has served as an independent director of Ingersoll Rand since July 2022 (years of service: 3). He is a senior advisor at General Atlantic and a senior partner at Flagship Pioneering; previously EVP & COO of Thermo Fisher Scientific (2017–2022), EVP & President of Life Sciences Solutions at Thermo Fisher (from 2014, via Life Technologies acquisition), and earlier President & COO of Life Technologies and Applied Biosystems. He holds an MBA from Henley Management College (UK) and a BSc in Chemistry from the University of Reading (UK). His experience leading growth businesses in life sciences and machine learning systems aligns with IR’s strategy in sustainable end markets and digital/IIoT innovation .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Thermo Fisher Scientific Inc. | Executive Vice President & Chief Operating Officer | 2017–2022 | Led operations at a Fortune 100 leader serving science; experience leading a “growth compounder” in sustainable end markets |
| Thermo Fisher Scientific Inc. | EVP & President, Life Sciences Solutions (via Life Technologies acquisition) | From 2014 | Scaled life sciences portfolio and operations |
| Life Technologies | President & Chief Operating Officer | — (prior to Thermo Fisher role; specific years not disclosed) | Operations leadership in life sciences |
| Applied Biosystems | President & Chief Operating Officer | Prior to 2008 merger with Invitrogen | Led operations before 2008 merger |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| General Atlantic | Senior Advisor | Current (as of 2025 proxy) | Growth equity advisory; sector expertise |
| Flagship Pioneering | Senior Partner | Current (as of 2025 proxy) | Life sciences venture building and investment |
Board Governance
| Item | Detail |
|---|---|
| Independence | Determined independent under IR Corporate Governance Guidelines and NYSE rules; independent for purposes of Exchange Act Section 10C(a)(3) (Compensation Committee) . |
| Committees (2024 activity) | Compensation Committee – Member; Nominating & Corporate Governance Committee – Member . |
| Committee chairs | Not a chair; Compensation Committee chaired by Kirk E. Arnold; Nominating & Corporate Governance Committee chaired by William P. Donnelly . |
| Meetings | Board held 6 meetings in 2024; committees held: Audit 4, Compensation 4, Nominating & Corporate Governance 4, Sustainability 3 . |
| Attendance | All nominees (including Stevenson) attended >75% of aggregate Board and applicable committee meetings in 2024 (meets minimum requirement) . |
| Executive sessions | Regular meetings of independent directors; presided over by Lead Director (William P. Donnelly) . |
| Board evaluations | Annual Board and committee performance assessments overseen by an independent firm . |
Fixed Compensation
| Year | Fees Earned or Paid in Cash ($) | Stock Awards ($) | Total ($) |
|---|---|---|---|
| 2024 | 80,625 | 192,500 | 273,125 |
Director program changes in 2024: annual cash retainer increased from $75,000 to $82,500 (effective Apr 1, 2024); annual RSU award increased from $175,000 to $192,500 (effective for Feb 2024 grant). Additional RSU awards: Audit Chair $25,000 and Audit members $10,000; Chair of Compensation/Nominating & Governance/Sustainability $15,000 (Comp Chair increased to $20,000 effective Apr 1, 2024); Lead Director $35,000. No meeting fees; reasonable expenses reimbursed. No changes for 2025 .
Performance Compensation
| Instrument | Grant/Units | Vesting | Fair Value ($) | Notes |
|---|---|---|---|---|
| RSUs (annual director grant) | 2,129 RSUs outstanding as of Dec 31, 2024 | Vested in full on Feb 27, 2025; standard schedule is one-year vesting on anniversary of grant date | 192,500 (2024 grant-date fair value) | Equity-focused director pay aligns interests; no option awards disclosed for directors . |
Other Directorships & Interlocks
| Category | Detail |
|---|---|
| Current public company boards | None disclosed in IR’s 2025 proxy biography for Stevenson . |
| Compensation Committee interlocks | None – no current Comp Committee member (including Stevenson) has served as an IR executive; no interlocking arrangements with executives of other companies in FY2024 . |
Expertise & Qualifications
- Life sciences operating executive with Fortune 100 scale; former EVP & COO, Thermo Fisher Scientific .
- Experience leading “growth compounder” in sustainable end markets (life sciences/medical), aligned with IR’s strategy .
- Machine learning systems experience supporting digitalization and IIoT initiatives .
- Education: MBA (Henley Management College, UK); BSc Chemistry (University of Reading, UK) .
Equity Ownership
| Item | Stevenson |
|---|---|
| Beneficial ownership (shares) | 9,397 (as of Apr 17, 2025) |
| Percent of common shares outstanding | <1% (403,447,247 shares outstanding as of Apr 17, 2025) |
| RSUs outstanding at 12/31/2024 | 2,129 RSUs; vested in full on Feb 27, 2025 |
| Stock ownership guidelines | Directors must hold 75% of net shares until holdings equal 5x annual cash retainer; as of Jan 1, 2025, all then-serving directors with ≥1 year were in compliance |
| Hedging/pledging | Company policy prohibits hedging and pledging of IR securities by directors |
Governance Assessment
- Independence and committee influence: Stevenson is an independent director and serves on the Compensation Committee (independent under Section 10C(a)(3)) and Nominating & Corporate Governance Committee, directly involved in executive pay oversight, board refreshment, and governance processes .
- Engagement and attendance: Met required attendance threshold (>75%) in 2024; Board held 6 meetings, and his committees were active (4 meetings each), indicating regular engagement .
- Pay alignment and shareholder support: Director pay is equity-focused (RSUs) with one-year vesting; no meeting fees; 2024 say-on-pay received 95% support, signaling broad investor alignment with compensation oversight in which Stevenson participates .
- Conflicts and related-party oversight: No related person transactions requiring disclosure since Jan 1, 2024; IR enforces anti-hedging/anti-pledging policies; the Audit Committee oversees related-party approvals—factors that reduce conflict risk .
- Board process quality: Annual independent evaluations, regular executive sessions under an independent Lead Director, and explicit risk oversight across committees (including cybersecurity) support board effectiveness .
No RED FLAGS identified in the proxy disclosure related to Stevenson: independence affirmed, attendance threshold met, no related-party transactions disclosed, and anti-hedging/pledging policies in place .
Citations: